A Randomized Phase II Study of Androgen Deprivation Therapy with or without Palbociclib in RB-positive Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

BACKGROUND: Palbociclib, a CDK4/6 inhibitor, blocks proliferation and in a Rb and Cyclin D dependent manner in preclinical prostate cancer models. We hypothesized that co-targeting AR and cell-cycle with palbociclib would improve outcomes in patients with metastatic hormone sensitive prostate cancer...

詳細記述

保存先:
書誌詳細
出版年:Clin Cancer Res
主要な著者: Palmbos, Phillip L., Daignault-Newton, Stephanie, Tomlins, Scott A., Agarwal, Neeraj, Twardowski, Przemyslaw, Morgans, Alicia K., Kelly, Wm. Kevin, Arora, Vivek K., Antonarakis, Emmanuel S., Siddiqui, Javed, Jacobson, Jon A., Davenport, Matthew S., Robinson, Dan, Chinnaiyan, Arul M., Knudsen, Karen E., Hussain, Maha
フォーマット: Artigo
言語:Inglês
出版事項: 2021
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC8246588/
https://ncbi.nlm.nih.gov/pubmed/33727260
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-21-0024
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料